Attached files

file filename
EX-99.1 - EXHIBIT 99.1 PRESIDENT’S REPORT TO SHAREHOLDERS DATED NOVEMBER 8, 2017 - Zivo Bioscience, Inc.f8k110717_ex99z1.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 8, 2017

 

ZIVO BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

 

000-30415

 

87-0699977

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number)

 

Identification No.)

 

 

2804 Orchard Lake Road, Suite 202, Keego Harbor, Michigan 48320

(Address of principal executive offices) (Zip Code)

 

Registrant's telephone number, including area code (248) 452-9866

 

Not applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[   ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[   ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[   ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[   ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 8.01 Other Events

 

On November 8, 2017 the Company released the President’s Report To Shareholders dated November 8, 2017, a copy of which is filed herewith as Exhibit 99.1.

 

Item 9.01 Financial Statements and Exhibits

 

Exhibit 99.1 – President’s Report to Shareholders dated November 8, 2017.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

HEALTH ENHANCEMENT PRODUCTS, INC.

 

 

Date: November 8, 2017By: /s/ Philip M. Rice, II 

Philip M. Rice, II,

Chief Financial Officer